From bioinks to bioprinters
We offer premium bioinks, bioprinters and services that enable critical breakthroughs in 3D cell culturing, tissue engineering and drug development.
By releasing the first universal bioink in 2016, we democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into the thriving $1 billion industry it is today.
Our best-in-class bioinks, bioprinters, software and services are being used by the foremost academics and R&D labs and have enabled critical breakthroughs in a wide range of applications from 3D cell culturing to tissue engineering to drug development.
CELLINK is dedicated to taking the on-demand biofabrication of human organs and tissues to the next level, in line with BICO’s vision to leverage bioconvergence in the life sciences and create the future of health.
We leverage the talents and enthusiasm of more than 180 engineers, scientists, financial experts and sales and marketing specialists to nurture the research and development of innovative life-science products and technologies for a wide range of applications and industries.
Transforming ideas into revolutionary products
We are growing!
A BICO company
CELLINK is proud to be part of BICO.
Founded in 2016, BICO is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, BICO’s innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
BICO has over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.